NicOx’s NO donating technology has proved popular in areas of drug reformulation leading to a number of deals with big pharma. NicOx upgraded its preclinical research programs with Pfizer and Merck & Co. into extended development agreements that are worth multiple million of euros. These collaborations focus on the evaluation of NO-donating compounds in areas decided by the big pharma partners, combined with the development of NicOx’s own therapeutics to later clinical stages.